Discovered and validated a synergistic combination of DNA repair inhibitors (ATR and PARP inhibitors) for targeting IDH1/2 mutant cancers. Selected as Editor’s Choice.
Recommended citation: Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. (2021). “Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.” NAR Cancer. 3(2):zcab018.